<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640341</url>
  </required_header>
  <id_info>
    <org_study_id>552</org_study_id>
    <nct_id>NCT00640341</nct_id>
  </id_info>
  <brief_title>Comparative Performance of PureVision, Acuvue Oasys and O2Optix</brief_title>
  <official_title>Product Performance of Bausch &amp; Lomb PureVisionÂ® Contact Lens When Compared to Johnson &amp; Johnson Acuvue Oasys Contact Lens and the Ciba Vision O2Optix Contact Lens Worn Daily.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the performance of the PureVision Contact Lens
      compared to Acuvue Oasys Contact lens and O2Optix Contact lens when worn on a daily wear
      basis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any Slit Lamp Finding &gt; Grade 2</measure>
    <time_frame>Over all follow-up visits for the 1 month study period</time_frame>
    <description>All dispensed eyes over all follow-up visits. Measured on a scale of 0-4 with 0=no findings and 4=severe findings. Epithelial edema, epithelial microcysts, corneal staining, limbal &amp; bulbar injection, conjunctival abnormalities, corneal neovascularization and infiltrates were measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Responses to Comfort-related Symptoms/Complaints</measure>
    <time_frame>Over all follow-up visits for 1 month study period</time_frame>
    <description>Subjective ratings of symptoms/complaints using a scale of 0 = Severe Stinging/Burning to 100 = No Stinging/Burning for each eye; 0 represented the least favorable rating and a 100 represented the most favorable rating.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncorrected Distance High Contrast Visual Acuity</measure>
    <time_frame>Over all visits for the 1 month study period</time_frame>
    <description>logMAR high contrast visual acuity (VA) over all visits.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">510</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>PureVision</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PureVision Contact Lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acuvue Oasys</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acuvue Oasys Contact Lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O2Optix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>O2Optix Contact Lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PureVision Contact Lens</intervention_name>
    <description>contact lens for daily wear</description>
    <arm_group_label>PureVision</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acuvue Oasys Contact Lens</intervention_name>
    <description>contact lens for daily wear</description>
    <arm_group_label>Acuvue Oasys</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>O2Optix Contact lens</intervention_name>
    <description>contact lens for daily wear</description>
    <arm_group_label>O2Optix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is myopic

          -  VA correctable to 0.3 LogMAR or better (driving vision)

          -  Clear central cornea

          -  Subject uses a lens care system on a regular basis

        Exclusion Criteria:

          -  Systemic disease affecting ocular health

          -  Using systemic or topical medications

          -  Wear monovision, multifocal or toric contact lenses

          -  Any grade 2 or greater slit lamp findings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Cairns, MCOptom, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Anderson, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anderson &amp; Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anderson &amp; Associates</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <results_first_submitted>February 3, 2011</results_first_submitted>
  <results_first_submitted_qc>March 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2011</results_first_posted>
  <last_update_submitted>December 7, 2011</last_update_submitted>
  <last_update_submitted_qc>December 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>546 subjects (1092 eyes) were planned to be enrolled at 26 investigative sites in the US. First subject enrolled on 2/25/2008 and last subject seen was 4/28/2008.</recruitment_details>
      <pre_assignment_details>510 subjects (1020 eyes) were enrolled (all were dispensed). 477 subjects (954 eyes) completed the study. 10 subjects were ineligible at baseline and 23 were discontinued during the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PureVision</title>
          <description>Redesigned PureVision Contact Lens. Lenses are to be worn on a daily wear basis.</description>
        </group>
        <group group_id="P2">
          <title>Acuvue Oasys</title>
          <description>Currently marketed Acuvue Oasys Contact Lens. Lenses are to be worn on a daily wear basis.</description>
        </group>
        <group group_id="P3">
          <title>O2Optix</title>
          <description>Currently marketed O2Optix Contact Lens. Lenses are to be worn on a daily wear basis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170">All Starting participants were dispensed lenses</participants>
                <participants group_id="P2" count="170"/>
                <participants group_id="P3" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible Participants at Baseline</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive Slit Lamp Findings</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Related Symptoms/Complaints</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inability to Maintain Wearing Schedule</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Follow Subject Instructions</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unacceptable Lens Movement</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor fit/Uncomfortable</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligable at Baseline</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event and positive slit lamp</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PureVision</title>
          <description>Redesigned PureVision Contact Lens. Lenses are to be worn on a daily wear basis.</description>
        </group>
        <group group_id="B2">
          <title>Acuvue Oasys</title>
          <description>Currently marketed Acuvue Oasys Contact Lens. Lenses are to be worn on a daily wear basis.</description>
        </group>
        <group group_id="B3">
          <title>O2Optix</title>
          <description>Currently marketed O2Optix Contact Lens. Lenses are to be worn on a daily wear basis.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="165"/>
            <count group_id="B2" value="167"/>
            <count group_id="B3" value="168"/>
            <count group_id="B4" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Age 18 to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="168"/>
                    <measurement group_id="B4" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="168"/>
                    <measurement group_id="B4" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Any Slit Lamp Finding &gt; Grade 2</title>
        <description>All dispensed eyes over all follow-up visits. Measured on a scale of 0-4 with 0=no findings and 4=severe findings. Epithelial edema, epithelial microcysts, corneal staining, limbal &amp; bulbar injection, conjunctival abnormalities, corneal neovascularization and infiltrates were measured.</description>
        <time_frame>Over all follow-up visits for the 1 month study period</time_frame>
        <population>All dispensed eyes</population>
        <group_list>
          <group group_id="O1">
            <title>PureVision</title>
            <description>Redesigned PureVision Contact Lens. Lenses are to be worn on a daily wear basis.</description>
          </group>
          <group group_id="O2">
            <title>Acuvue Oasys</title>
            <description>Currently marketed Acuvue Oasys Contact Lens. Lenses are to be worn on a daily wear basis.</description>
          </group>
          <group group_id="O3">
            <title>O2Optix</title>
            <description>Currently marketed O2Optix Contact Lens. Lenses are to be worn on a daily wear basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Any Slit Lamp Finding &gt; Grade 2</title>
          <description>All dispensed eyes over all follow-up visits. Measured on a scale of 0-4 with 0=no findings and 4=severe findings. Epithelial edema, epithelial microcysts, corneal staining, limbal &amp; bulbar injection, conjunctival abnormalities, corneal neovascularization and infiltrates were measured.</description>
          <population>All dispensed eyes</population>
          <units>Eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="168"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="338"/>
                <count group_id="O3" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Responses to Comfort-related Symptoms/Complaints</title>
        <description>Subjective ratings of symptoms/complaints using a scale of 0 = Severe Stinging/Burning to 100 = No Stinging/Burning for each eye; 0 represented the least favorable rating and a 100 represented the most favorable rating.</description>
        <time_frame>Over all follow-up visits for 1 month study period</time_frame>
        <population>All eligible dispensed eyes.</population>
        <group_list>
          <group group_id="O1">
            <title>PureVision</title>
            <description>Redesigned PureVision Contact Lens. Lenses are to be worn on a daily wear basis.</description>
          </group>
          <group group_id="O2">
            <title>Acuvue Oasys</title>
            <description>Currently marketed Acuvue Oasys Contact Lens. Lenses are to be worn on a daily wear basis.</description>
          </group>
          <group group_id="O3">
            <title>O2Optix</title>
            <description>Currently marketed O2Optix Contact Lens. Lenses are to be worn on a daily wear basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Responses to Comfort-related Symptoms/Complaints</title>
          <description>Subjective ratings of symptoms/complaints using a scale of 0 = Severe Stinging/Burning to 100 = No Stinging/Burning for each eye; 0 represented the least favorable rating and a 100 represented the most favorable rating.</description>
          <population>All eligible dispensed eyes.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="164"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="334"/>
                <count group_id="O3" value="328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning Comfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" spread="17.55"/>
                    <measurement group_id="O2" value="92.9" spread="11.97"/>
                    <measurement group_id="O3" value="92.0" spread="12.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comfort Throughout the Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9" spread="18.94"/>
                    <measurement group_id="O2" value="90.1" spread="14.47"/>
                    <measurement group_id="O3" value="88.4" spread="13.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Day Comfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="21.86"/>
                    <measurement group_id="O2" value="85.2" spread="16.69"/>
                    <measurement group_id="O3" value="81.4" spread="18.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lens Awareness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" spread="23.46"/>
                    <measurement group_id="O2" value="89.5" spread="16.30"/>
                    <measurement group_id="O3" value="86.4" spread="17.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" spread="20.15"/>
                    <measurement group_id="O2" value="90.5" spread="14.42"/>
                    <measurement group_id="O3" value="87.0" spread="15.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9" spread="15.75"/>
                    <measurement group_id="O2" value="93.5" spread="12.81"/>
                    <measurement group_id="O3" value="92.2" spread="13.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dryness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" spread="20.22"/>
                    <measurement group_id="O2" value="89.1" spread="14.42"/>
                    <measurement group_id="O3" value="85.0" spread="17.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0" spread="14.93"/>
                    <measurement group_id="O2" value="94.5" spread="11.14"/>
                    <measurement group_id="O3" value="91.9" spread="14.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Uncorrected Distance High Contrast Visual Acuity</title>
        <description>logMAR high contrast visual acuity (VA) over all visits.</description>
        <time_frame>Over all visits for the 1 month study period</time_frame>
        <population>All eligible dispensed eyes.</population>
        <group_list>
          <group group_id="O1">
            <title>PureVision</title>
            <description>Redesigned PureVision Contact Lens. Lenses are to be worn on a daily wear basis.</description>
          </group>
          <group group_id="O2">
            <title>Acuvue Oasys</title>
            <description>Currently marketed Acuvue Oasys Contact Lens. Lenses are to be worn on a daily wear basis.</description>
          </group>
          <group group_id="O3">
            <title>O2Optix</title>
            <description>Currently marketed O2Optix Contact Lens. Lenses are to be worn on a daily wear basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Uncorrected Distance High Contrast Visual Acuity</title>
          <description>logMAR high contrast visual acuity (VA) over all visits.</description>
          <population>All eligible dispensed eyes.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="168"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="334"/>
                <count group_id="O3" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.031" spread="0.070"/>
                    <measurement group_id="O2" value="-0.026" spread="0.071"/>
                    <measurement group_id="O3" value="-0.024" spread="0.0760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PureVision</title>
          <description>Redesigned PureVision Contact Lens. Lenses are to be worn on a daily wear basis.</description>
        </group>
        <group group_id="E2">
          <title>Acuvue Oasys</title>
          <description>Currently marketed Acuvue Oasys Contact Lens. Lenses are to be worn on a daily wear basis.</description>
        </group>
        <group group_id="E3">
          <title>O2Optix</title>
          <description>Currently marketed O2Optix Contact Lens. Lenses are to be worn on a daily wear basis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Cairns</name_or_title>
      <organization>Bausch &amp; Lomb Incorporated</organization>
      <phone>(585) 338-5170</phone>
      <email>gerard.cairns@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

